Flash Finance

Dishman Carbogen Amcis LimitedDCALCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹149.83
MCap ₹2,349 Cr · P/E 145.7
Dishman Carbogen Amcis Limited — Stock analysis & AI research Dishman Carbogen Amcis Limited — Seasonality — best & worst months Dishman Carbogen Amcis Limited — Technical indicators & charts Dishman Carbogen Amcis Limited — Technical setup — score, trend, support & resistance Dishman Carbogen Amcis Limited — Live exchange announcements
📋 Stocks Below Book Value 📈 MACD Bullish Crossover📈 Multi-Timeframe Bearish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹678 Cr
Sales · Jun 2026
-4.3% YoY
₹60 Cr
Operating Profit · Jun 2026
-57.4% YoY
8.9%
OPM % · Jun 2026
-55.3% YoY
₹-58 Cr
Net Profit · Jun 2026
-351.7% YoY
—
EPS · Jun 2026

📝 Dishman Carbogen Amcis Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Dishman Carbogen Amcis Limited reported revenue of ₹678 crore for the quarter ended June 2026 (Q1 FY27), down 4.3% from ₹708 crore in the same quarter last year, and down 20.4% sequentially over the March 2026 quarter.

The company reported a net loss of ₹58 crore, against a net profit of ₹23 crore in the same quarter last year.

Operating profit stood at ₹60 crore — an operating margin (OPM) of 8.9%, compared with 19.9% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Dishman Carbogen Amcis Limited posted revenue of ₹2,932 crore, a growth of 8.1% over FY25, with a net profit of ₹97 crore (up 2655.7% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,902 crore with a net profit of ₹16 crore.

Valuation snapshot

At the current price of ₹149.83, DCAL has a market capitalisation of ₹2,349 crore and a trailing P/E of about 145.7.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 19th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 59.32%, foreign institutional investors (FIIs) 6.86%, domestic institutional investors (DIIs) 2.07%, public shareholders 31.75% of Dishman Carbogen Amcis Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹2,349 Cr
Current Price ?
₹149.8
P/E ?
145.72above ind
Industry P/E ?
37.20
P/B ?
0.35
P/S ?
0.81
P/FCF ?
10.44
Enterprise Value ?
₹5,425 Cr
EV/EBITDA ?
11.18
PEG ?
1.04
Earnings Yield ?
2.5%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹2,902 Cr
OPM ?
16.7%
Profit after tax (TTM) ?
₹16 Cr
EPS (TTM) ?
₹1.03
ROCE ?
3.0%
ROE ?
0.2%
ROA ?
0.1%
Growth
Sales — latest qtr ?
₹678 Cr
PAT — latest qtr ?
₹-58 Cr
YoY qtr sales growth ?
-4.3%
YoY qtr profit growth ?
-351.7%
Sales growth (3y) ?
7%
Sales growth (5y) ?
9%
Profit growth (3y) ?
140%
Profit growth (5y) ?
21%
Financial Health
Debt ?
₹3,076 Cr
Debt to Equity ?
0.46
Interest Coverage ?
1.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
59.32%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-21.7%
Return 6 months ?
-11.1%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 78619723587651111524789682716708653720851678 -4.3% -20.4%
Operating Profit -3511226141122914714015314114911316360 -57.4% -63.1%
Other Income 12-39756-3148822871518 -17.5% +21.1%
Interest 152428273316323749424342464337 -13.7% -13.7%
Depreciation 37670758026717272798184848991 +12.0% +1.9%
Profit Before Tax -10-8829-36-66-34-784227283931-1046-51 -231.3% -211.3%
Net Profit -7-7117-41-60-31-78335432365-1322-58 -351.7% -363.1%
EPS -0.42-4.511.08-2.61-3.80-1.98-4.952.110.302.751.494.16-0.831.39— — —
OPM % -4.1% 8.2% 16.9% 10.4% 6.3% 10.4% 5.5% 18.6% 20.5% 21.3% 19.9% 22.8% 15.7% 19.2% 8.9% -55.3% -53.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹2,711 Cr ₹2,932 Cr ₹2,902 Cr +8.1%
Operating Profit ₹469 Cr ₹566 Cr ₹485 Cr +20.8%
OPM % 17.29% 19.30% 16.72% +11.6%
NPM % 0.13% 3.31% 0.56% +2446.2%
Other Income ₹21 Cr ₹52 Cr ₹48 Cr +143.0%
Depreciation ₹294 Cr ₹338 Cr ₹348 Cr +15.1%
Interest ₹160 Cr ₹174 Cr ₹168 Cr +8.7%
EBIT ₹175 Cr ₹228 Cr ₹137 Cr +30.3%
PBT ₹19 Cr ₹106 Cr ₹16 Cr +453.8%
Tax ₹-15 Cr — ₹7 Cr —
Net Profit ₹4 Cr ₹97 Cr ₹16 Cr +2655.7%
EPS ₹0.21 ₹6.21 ₹4.72 +2857.1%
Material Cost ₹215 Cr — ₹145 Cr —
Employee Cost ₹642 Cr — ₹389 Cr —
Extraordinary Items ₹-17 Cr — ₹-2 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 31313131 +0.0%
Reserves 5,7785,5965,8006,646 +14.6%
Borrowings 2,2092,3132,3893,076 +28.8%
Other Liabilities 1,4211,6311,7662,170 +22.9%
Total Liabilities 9,4399,5719,98711,923 +19.4%
Fixed Assets 6,1886,7247,0558,371 +18.7%
CWIP 1,043646467275 -41.1%
Investments 2491029791 -6.2%
Other Assets 1,9592,0982,3683,186 +34.5%
Total Assets 9,4399,5719,98711,923 +19.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
CFO/OP 90%139%86%88% +2.3%
Cash from Operating Activity 266379375491 +30.9%
Cash from Investing Activity -494-225-196-245 -25.0%
Cash from Financing Activity 250-22-102201 +297.1%
Net Cash Flow 2213277447 +480.5%
Free Cash Flow -35276160225 +40.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 89689084 -6.7%
Inventory Days 568540655910 +38.9%
Days Payable 155149168189 +12.5%
Cash Conversion Cycle 502458577805 +39.5%
Working Capital Days -37-148-35-58 -65.7%
ROCE % 1%0%2%3% +50.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 59.32%59.32%59.32%59.32%59.32% +0.0%
FIIs 9.94%8.07%7.66%7.45%6.86% -7.9%
DIIs 1.27%1.37%1.27%1.63%2.07% +27.0%
Public 29.48%31.23%31.75%31.60%31.75% +0.5%
No. of Shareholders 49,74449,45548,48149,00949,430 +0.9%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Dishman Carbogen Amcis Limited's revenue in Q1 FY27?
Dishman Carbogen Amcis Limited reported revenue of ₹678 crore for the quarter ended June 2026 (Q1 FY27), down 4.3% from ₹708 crore in the same quarter last year, and down 20.4% sequentially over the March 2026 quarter.
What was Dishman Carbogen Amcis Limited's net profit in Q1 FY27?
The company reported a net loss of ₹58 crore, against a net profit of ₹23 crore in the same quarter last year.
What is DCAL's market capitalisation and P/E ratio?
At the current price of ₹149.83, DCAL has a market capitalisation of ₹2,349 crore and a trailing P/E of about 145.7.
Who owns Dishman Carbogen Amcis Limited? (shareholding pattern)
As of Jun 2026, promoters held 59.32%, foreign institutional investors (FIIs) 6.86%, domestic institutional investors (DIIs) 2.07%, public shareholders 31.75% of Dishman Carbogen Amcis Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI